GL1X · GenesisL1 explorer

MolNFT v1 · #189298 · protein

Arsenic-bound P53 DNA-binding domain mutant V272M

7V97 · Cellular tumor antigen P53: “Arsenic-bound P53 DNA-binding domain mutant V272M”. X-ray diffraction, 2 ligands (ARS, ZN), 14 pockets (best druggability 0.57). MolNFT v1 #189298 on GenesisL1: 3D structure, binding sites and pockets in…

PDB
7V97
Type
protein
Length
773 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Cellular tumor antigen P53
UniProt
P04637
Ligands
ARS, ZN
Pockets
14 · best druggability 0.57

Structure

x-ray diffraction · 3 distinct chains · 8% helix, 34% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, CCellular tumor antigen P53protein1948% helix, 34% strandP04637
BCellular tumor antigen P53protein1938% helix, 34% strandP04637
DCellular tumor antigen P53protein1928% helix, 34% strandP04637

Ligands and binding sites

  • ARS · Arsenic · metal · 4 copies · chains A, B, C, D
  • ZN · Zinc ion · metal · 4 copies · chains A, B, C, D

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

14 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13120.570.7740empty
23440.550.7440empty
33010.530.7549empty
42310.520.7641empty
52510.500.7425empty

Interfaces

5 interfaces between chains.

  • C–D · 594 Ų buried · 8 hydrogen bonds · protein-protein
  • A–B · 582 Ų buried · 7 hydrogen bonds · protein-protein
  • A–C · 437 Ų buried · 7 hydrogen bonds · protein-protein
  • B–D · 223 Ų buried · 1 hydrogen bond · protein-protein
  • B–C · 18 Ų buried · 0 hydrogen bonds · protein-protein

Compared structures

  • 7V97 · Arsenic-bound p53 DNA-binding domain mutant V272M · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.